| Identification | Back Directory | [Name]
6-Fluoro-2-[4-(pyridin-2-yl)-3-butynyl]imidazo[1,2-a]pyridine | [CAS]
872363-17-2 | [Synonyms]
ADX48621
ADX 48621
Icosabutate
Dipraglurant
6-Fluoro-2-[4-(pyridin-2-yl)-3-butynyl]imidazo[1,2-a]pyridine
6-fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]-Imidazo[1,2-a]pyridine
Imidazo[1,2-a]pyridine, 6-fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]- | [Molecular Formula]
C16H12FN3 | [MDL Number]
MFCD18633187 | [MOL File]
872363-17-2.mol | [Molecular Weight]
265.29 |
| Chemical Properties | Back Directory | [density ]
1.16 | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Powder | [pka]
5.59±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Dipraglurant (ADX48621) is a potent, selective, orally active and brain penetrant mGluR5 negative allosteric modulator (NAM), with an IC50 of 21 nM. Dipraglurant can reduce Levodopa-induced dyskinesia (LID) in vivo[1][2]. Dipraglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | [in vivo]
Dipraglurant (3-30 mg/kg; a single p.o.) reduces L-dopa-induced chorea and dystonia and does not interfere with the ef?cacy of L-dopa in treating parkinsonian disability macaque[1].
Dipraglurant exhibits Cmax (1.040, 1.380, 5.310 ng/mL) Tmax (1.0, 0.5, 1.0 h) and AUCinf (2.230, 2.860, 15.700) following p.o. administration (3, 10, 30 mg/kg) in macaque[1]. | [IC 50]
mGluR5: 21 nM (IC50) | [References]
[1] The Synthesis and Use of Certain Pyridine Derivatives as Modulators of the G-protein Coupled Receptors mGlu5 and P2Y12
[2] Bezard E, et, al. The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. Mov Disord. 2014 Jul;29(8):1074-9. DOI:10.1002/mds.25920
[3] Sciamanna G, et, al. Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia. Neuropharmacology. 2014 Oct;85:440-50. DOI:10.1016/j.neuropharm.2014.06.013 |
|
|